Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.33 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.33 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11842318 | 0.85 | — | — | |
| SCHEMBL16199447 | 0.77 | DNM1 (0.38) | — | |
| SCHEMBL16199441 | 0.77 | DNM1 (0.38) | — | |
| SCHEMBL21397877 | 0.76 | ADRB2 (0.36) | TSHRALDH1A1ADRB2ADRB1ADRB3 | |
| SCHEMBL3835004 | 0.76 | ADRB2 (0.36) | TSHRALDH1A1ADRB2ADRB1ADRB3 | |
| SCHEMBL3634744 | 0.74 | TSHR (0.32) | TSHRALDH1A1ADRB2ADRB1ADRB3 | |
| SCHEMBL108259 | 0.72 | TSHR (0.42) | TSHRALDH1A1ADRB2ADRB1ADRB3 | |
| SCHEMBL337285 | 0.72 | — | — | |
| SCHEMBL2363637 | 0.70 | TSHR (0.40) | TSHRALDH1A1ADRB2ADRB1ADRB3 | |
| SCHEMBL7081314 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025228947-A1 | BIFUNCTIONAL COMPOUNDS CAPABLE OF INDUCING DEGRADATION OF POLO-LIKE KINASE1 | CROSSFIRE ONCOLOGY B.V. (NL) | 2025-11-06 | — | — | WO | disclosed |
| EP-3716982-A1 | ANTI-CD40 ANTIBODY DRUG CONJUGATES | AbbVie Inc. (US) | 2020-10-07 | — | — | EP | disclosed |
| EP-2714092-B1 | IMMUNOCONJUGATES, COMPOSITIONS CONTAINING THEM, AND METHODS OF MAKING AND USE | BRISTOL MYERS SQUIBB CO (US) | 2020-07-15 | — | — | EP | disclosed |
| US-20140364585-A1 | IMMUNOCONJUGATES, COMPOSITIONS FOR MAKING THEM, AND METHODS OF MAKING AND USE | BRISTOL-MYERS SQUIBB COMPANY | 2014-12-11 | — | — | US | disclosed |
| WO-2012162482-A1 | IMMUNOCONJUGATES, COMPOSITIONS CONTAINING THEM, AND METHODS OF MAKING AND USE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-29 | — | — | WO | disclosed |
| WO-2009129401-A1 | KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-22 | — | — | WO | disclosed |
| EP-2102201-A2 | SUBSTITUTED DIAZEPINE SULFONAMIDES AS BOMBESIN RECEPTOR SUBTYPE-3 MODULATORS | Merck & Co., Inc. (US) | 2009-09-23 | — | — | EP | disclosed |
| EP-2081930-A2 | KINASE INHIBITORS | Takeda San Diego, Inc. (US) | 2009-07-29 | — | — | EP | disclosed |
| EP-2079696-A2 | KINASE INHIBITORS | Takeda San Diego, Inc. (US) | 2009-07-22 | — | — | EP | disclosed |
| WO-2008073311-A2 | SUBSTITUTED DIAZEPINE SULFONAMIDES AS BOMBESIN RECEPTOR SUBTYPE-3 MODULATORS | MERCK & CO., INC. (US) | 2008-06-19 | — | — | WO | disclosed |
| WO-2005102997-A1 | 3,4-DISUBSTITUTED MALEIMIDES FOR USE AS VASCULAR DAMAGING AGENTS | ASTRAZENECA AB (SE) | 2005-11-03 | — | — | WO | disclosed |
| EP-1578755-A1 | PHOSPHONOOXY QUINAZOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | AstraZeneca AB (SE) | 2005-09-28 | — | — | EP | disclosed |
| EP-1575946-A1 | QUINAZOLINE COMPOUNDS | AstraZeneca AB (SE) | 2005-09-21 | — | — | EP | disclosed |
| EP-1575966-A1 | THERAPEUTIC QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2005-09-21 | — | — | EP | disclosed |
| US-20040142854-A1 | Compounds and methods for stimulating beta-catenin mediated gene expression and differentiation | ADHEREX TECHNOLOGIES, INC. (CA) | 2004-07-22 | — | — | US | disclosed |
| WO-2004058752-A1 | QUINAZOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2004-07-15 | — | — | WO | disclosed |
| WO-2004058781-A1 | PHOSPHONOOXY QUINAZOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | ASTRAZENECA AB (SE) | 2004-07-15 | — | — | WO | disclosed |
| WO-2004058782-A1 | THERAPEUTIC QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2004-07-15 | — | — | WO | disclosed |
| EP-0468998-A1 | PEPTIDES HAVING NOVEL POLAR N-TERMINAL GROUPS | THE UPJOHN COMPANY (US) | 1992-02-05 | — | — | EP | disclosed |
| WO-1990012804-A2 | PEPTIDES HAVING NOVEL POLAR N-TERMINAL GROUPS | THE UPJOHN COMPANY (US) | 1990-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140364585-A1 | IMMUNOCONJUGATES, COMPOSITIONS FOR MAKING THEM, AND METHODS OF MAKING AND USE | TOP1, TOP2B, OGG1 | TSHR 3435/4885ALDH1A1 1280/4885ADRB2 4658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.